Lv44
609 积分 2023-03-30 加入
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
3天前
已完结
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer
3天前
已完结
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer
3天前
已完结
Transgelin 2 guards T cell lipid metabolism and antitumour function
3天前
已完结
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair–Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D
9天前
已完结
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
9天前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
14天前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
16天前
已完结
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
16天前
已完结
BiTEing refractory RA
20天前
已完结
皖公网安备34019202002308
